Biopharma merger in UK

- Last updated on GMT

Related tags: Mergers and acquisitions

Spotlight on the home of the celebrated pork pie in England, with
the annoucement this week that Melton Mowbray-based Bridgehead
Technologies and Pharmalicensing - two biopharmaceutical business
development companies - are to merge.

Spotlight on the home of the celebrated pork pie in England, with the annoucement this week that Melton Mowbray-based Bridgehead Technologies and Pharmalicensing - two biopharmaceutical business development companies - are to merge.

Although the two companies will continue to trade under their own names, the merger will form The Bridgehead Pharmalicensing Group. In addition, a new product licensing and technology transfer service for medical and life sciences companies will be launched, backed by the companies joint expertise.

Bridgehead Technologies is a specialist consultancy that offers due diligence, valuation and strategy advice to the life sciences and medical technologies sectors. While Pharmalicensing describes itself as 'an online partner for biopharmaceutical business development.'

Dr Fiona Paton, Chairman of the new company commented this week :"The merger represents a strategic move in a business-critical discipline. We have identified product sourcing in the pharmaceutical, medical and life sciences industries as a major growth area in the industry."​David Alcraft, director of Bridgehead Technologies, echoed her words, stressing the competitive edge that the new merger will bring to both companies.

The group, looking to offer high-level support in areas of portfolio decision-making, product/corporate evaluation, intellectual property strategy, due diligence, setting and negotiating deal terms and pricing/reimbursement, will have offices and associates in all major countries, although the international headquarters will be in the UK.

Related topics: Markets & Regulations

Follow us

Products

View more

Webinars